Dr. Saint Fleur-Lominy on the Use of Ruxolitinib Versus Fedratinib in MPNs

Partner | Cancer Centers | <b>Perlmutter Cancer Center at NYU Langone</b>

Shella Saint Fleur-Lominy, MD, PhD, discusses the use of ruxolitinib (Jakafi) in the treatment of patients with myeloproliferative neoplasms.

Shella Saint Fleur-Lominy, MD, PhD, an assistant professor, Department of Medicine, at NYU Langone Health’s Perlmutter Cancer Center, discusses the use of ruxolitinib (Jakafi) in the treatment of patients with myeloproliferative neoplasms (MPNs).

The track record with ruxolitinib supports its use over fedratinib (Inrebic) in the treatment of patients with MPNs, according to Saint Fleur-Lominy. At the moment, physicians have more experience with administering ruxolitinib, as it was approved for use in myelofibrosis since 2011, says Saint Fleur-Lominy. Thus, those working in the field are familiar with the agent and feel comfortable adjusting the dosage if a patient experiences cytopenia. Patients can still experience benefit from ruxolitinib at a lower dosage, says Saint Fleur-Lominy.

For these reasons, most will gravitate toward the use of ruxolitinib in practice. However, per the National Comprehensive Cancer Network guidelines, fedratinib is also considered to be an option for patients with high-risk myelofibrosis, concludes Saint Fleur-Lominy.